Patients with diabetes mellitus (DM) and acute coronary syndromes have a greater level of platelet aggregation and a poor response to oral antiplatelet drugs. Clopidogrel is still widely used in clinical practice, despite the current evidence favoring ticagrelor and prasugrel.
The aim of this study was to investigate the determinants of clopidogrel use in the population of the multicenter prospective 'Acute Coronary Syndrome and Diabetes Registry' carried out during a 9-week period between March and May 2015 at 29 Hospitals.
- Ferlini M, Musumeci G, Grieco N, Rossini R, De Servi S, Mafrici A, Sponzilli C, Demarchi A, Assanelli EM, Camisasca P, Chizzola G, Corrada E, Farina A, Pedrinazzi C, Lettieri C, Oltrona Visconti L. The paradox of clopidogrel use in patients with acute coronary syndromes and diabetes: insight from the Diabetes and Acute Coronary Syndrome Registry. Coron Artery Dis 2018 Jan 5. doi: 10.1097/MCA.0000000000000601. [Epub ahead of print] Go to PubMed